Company intelligence / Profile preview
Verrica Pharmaceuticals
West Chester, Pennsylvania, United Statesverrica.com ↗
- Ownership
- Public · VRCA
- Development stage
- Other
01
Overview
Verrica Pharmaceuticals has achieved FDA approval for YCANTH (cantharidin) for molluscum contagiosum and is developing it for common warts. The company is also developing VP-315 for basal cell carcinoma and squamous cell carcinoma.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculesOncolytic peptides
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Lytix Biopharma ASTorii Pharmaceutical Co., Ltd.
04
Financials
- Market cap
- $53.1M
- Total revenue
- $35.6M
- Enterprise value
- $43.7M
Beyond the preview
Go deeper on Verrica Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Verrica Pharmaceuticals.